TB Vaccine Development: The Next Chapter Starts Now
On Thursday, April 13, Treatment Action Group (TAG) presented this webinar about important developments in TB vaccine research.
Why Viral Load Can Be Detectable Despite Perfect Adherence
Webinar on March 22 that will provide an update on new research into cases in which the HIV reservoir generates detectable viral load that cannot be suppressed by antiretroviral therapy.
TB Treatment Trial Results in Context for Communities
On Tuesday, March 14 at 8:00 am ET, join Treatment Action Group (TAG) and Dr. Jennifer Furin for an overview of key results and breakdown of how they fit into the larger TB policy and research landscapes.
Pathways Forward to End HIV: How HIV Cure Research is Helping to Advance HIV Vaccine Research
On September 20, please join Treatment Action Group, Dr. Shelly Karuna, and Dr. Karine Dubé for a webinar on the next generation of bnAbs trial design and ethics related to ATIs in HIV vaccine and cure research.
European Commitments to TB R&D Investments: Promises Made to Be Broken?
In this brief, TAG outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.
Update on HIV Vaccine Research
Developing an HIV vaccine is a difficult scientific challenge, but remains a critical priority. This handout provides an update on HIV vaccine research and a summary of results from the efficacy trials that have been conducted to date, and it…
HIV Research Advocacy Fact Sheet
HIV advocacy laid the foundation for much of the work we do today. This handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition. The handout provides a summary of the history…
New HIV Prevention Research Fact Sheet
HIV prevention research continues to rapidly evolve. The availability of pre-exposure prophylaxis (PrEP) has necessitated the development of new approaches to testing the efficacy of additional biomedical HIV prevention options. This handout was developed in collaboration with the Black AIDS…
Broadly Neutralizing Antibodies for HIV Prevention Fact Sheet
HIV-specific broadly neutralizing antibodies (bNAbs) could have a role in treating, preventing, or even curing HIV. Some HIV-specific bNAbs are already being tested in clinical trials, both for prevention and treatment. This handout was developed in collaboration with the Black…
Substantial Public Investments in GeneXpert Underscore Need for Affordable Pricing
TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.